Capricor Therapeutics Q1 2025: Assets vs. Liabilities
Ticker: CAPR · Form: 10-Q · Filed: May 14, 2025 · CIK: 1133869
| Field | Detail |
|---|---|
| Company | Capricor Therapeutics, Inc. (CAPR) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, balance-sheet, quarterly-report
TL;DR
Capricor's liabilities ($45.68M) just edged out its assets ($45.58M) as of March 31, 2025.
AI Summary
Capricor Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported total assets of $45.58 million and total liabilities of $45.68 million as of March 31, 2025. This indicates a slight negative equity position for the company.
Why It Matters
This filing provides a snapshot of Capricor Therapeutics' financial health, showing liabilities slightly exceeding assets, which could impact its ability to fund operations or future growth.
Risk Assessment
Risk Level: medium — The company's liabilities slightly exceeding its assets suggests potential financial strain or a need for further capital infusion.
Key Numbers
- $45.58M — Total Assets (As of March 31, 2025)
- $45.68M — Total Liabilities (As of March 31, 2025)
Key Players & Entities
- CAPRICOR THERAPEUTICS, INC. (company) — Filer
- March 31, 2025 (date) — Reporting period end date
- $45.58 million (dollar_amount) — Total assets as of March 31, 2025
- $45.68 million (dollar_amount) — Total liabilities as of March 31, 2025
FAQ
What was Capricor Therapeutics' net income or loss for the quarter ending March 31, 2025?
The provided excerpt does not contain specific net income or loss figures for the quarter ending March 31, 2025. It focuses on balance sheet items.
What are the primary components of Capricor's total assets as of March 31, 2025?
The excerpt lists various equity and retained earnings accounts but does not break down the specific components of the $45.58 million in total assets.
What is the nature of the liabilities that caused Capricor's total liabilities to exceed its total assets?
The provided text does not detail the specific types or amounts of liabilities contributing to the $45.68 million total liabilities.
Does the filing mention any significant financing activities or capital raises during the quarter ending March 31, 2025?
The excerpt does not provide information on financing activities or capital raises for the specified period.
What was the company's cash and cash equivalents balance as of March 31, 2025?
The provided text does not specify the cash and cash equivalents balance as of March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding CAPRICOR THERAPEUTICS, INC. (CAPR).